UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                  SCHEDULE 14A

                                 (Rule 14a-101)

                            SCHEDULE 14A INFORMATION

           Proxy Statement Pursuant to Section 14(a) of the Securities
                      Exchange Act of 1934 (Amendment No. )

Filed by the Registrant |X|

Filed by a Party other than the Registrant |_|

Check the appropriate box:

|_|   Preliminary Proxy Statement

|_|   Confidential, for Use of the Commission Only (as permitted by Rule
      14a-6(e)(2))

|X|   Definitive Proxy Statement

|_|   Definitive Additional Materials

|_|   Soliciting Material Pursuant to ss.240.14a-12

                              Innodata Isogen, Inc.
--------------------------------------------------------------------------------
                (Name of Registrant as Specified In Its Charter)

--------------------------------------------------------------------------------
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

|X|   No fee required.

|_|   Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

      1)    Title of each class of securities to which transaction applies:

--------------------------------------------------------------------------------

      2)    Aggregate number of securities to which transaction applies:

--------------------------------------------------------------------------------

      3)    Per unit price or other underlying value of transaction computed
            pursuant to Exchange Act Rule 0-11 (set forth the amount on which
            the filing fee is calculated and state how it was determined):

--------------------------------------------------------------------------------

      4)    Proposed maximum aggregate value of transaction:

--------------------------------------------------------------------------------

      5)    Total fee paid:

--------------------------------------------------------------------------------

|_|   Fee paid previously with preliminary materials.

--------------------------------------------------------------------------------

|_|   Check box if any part of the fee is offset as provided by Exchange Act
      Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
      paid previously. Identify the previous filing by registration statement
      number, or the Form or Schedule and the date of its filing.

      1)    Amount Previously Paid:

--------------------------------------------------------------------------------

      2)    Form, Schedule or Registration Statement No.:

--------------------------------------------------------------------------------

      3)    Filing Party:

--------------------------------------------------------------------------------

      4)    Date Filed:

--------------------------------------------------------------------------------


                               [LOGO](TM) INNODATA
                                          ISOGEN

                             Three University Plaza
                          Hackensack, New Jersey 07601

                    NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
                             TO BE HELD JUNE 7, 2005

To the Stockholders of Innodata Isogen, Inc.:

         The Annual  Meeting of  Stockholders  of  Innodata  Isogen,  Inc.  (the
"Company")  will be held at  Innodata  Isogen,  Inc.,  Three  University  Plaza,
Hackensack,  New Jersey 07601 at 11:00 A.M. on June 7, 2005,  for the  following
purposes:

(1)  To elect five Directors of the Company to hold office until the next Annual
     Meeting of Stockholders  and until their  successors have been duly elected
     and qualified;

(2)  To ratify the selection and appointment by the Company's Board of Directors
     of Grant Thornton LLP,  independent  auditors,  as auditors for the Company
     for the year ending December 31, 2005; and

(3)  To consider and transact  such other  business as may properly  come before
     the meeting or any adjournments thereof.

         A Proxy Statement, form of Proxy, and the Annual Report to Stockholders
of the Company for the year ended December 31, 2004 are enclosed herewith.  Only
holders of record of Common  Stock of the  Company at the close of  business  on
April 11, 2005 will be  entitled to notice of and to vote at the Annual  Meeting
and any adjournments  thereof.  A complete list of the stockholders  entitled to
vote will be available for inspection by any stockholder during the meeting;  in
addition,  the list will be open for  examination  by any  stockholder,  for any
purpose germane to the meeting,  during ordinary business hours, for a period of
at least ten days prior to the  meeting at the  office of the  Secretary  of the
Company, located at Three University Plaza, Hackensack, New Jersey 07601.

                                   By Order of the Board of Directors,


                                   Amy R. Agress
                                   Vice President, General Counsel and Secretary

Hackensack, New Jersey
April 19, 2005

         All stockholders are cordially invited to attend the Meeting. If you do
not expect to be present,  please sign and date the  enclosed  form of Proxy and
return it promptly using the enclosed envelope. No postage is required if mailed
in the United  States.  Any person  giving a Proxy has the power to revoke it at
any time prior to its exercise and if present at the Meeting may withdraw it and
vote in person.  Attendance  at the  Meeting is limited to  stockholders,  their
proxies and invited guests of the Company.


                              INNODATA ISOGEN, INC.
                             Three University Plaza
                          Hackensack, New Jersey 07601

                                 PROXY STATEMENT

         This Proxy Statement is furnished in connection  with the  solicitation
by the Board of Directors of Innodata Isogen, Inc. (the "Company") of proxies in
the  form  enclosed.  Such  Proxies  will be  voted  at the  Annual  Meeting  of
Stockholders  of  the  Company  to be  held  at  Innodata  Isogen,  Inc.,  Three
University  Plaza,  Hackensack,  New Jersey  07601 at 11:00 A.M. on June 7, 2005
(the  "Meeting") and at any  adjournments  thereof for the purposes set forth in
the accompanying Notice of Annual Meeting of Stockholders.

         This Proxy  Statement  and  accompanying  Proxy are being  mailed on or
about May 6, 2005 to all  stockholders  of record on April 11, 2005 (the "Record
Date").

         Any stockholder  giving a Proxy has the power to revoke the same at any
time before it is voted.  The cost of  soliciting  Proxies  will be borne by the
Company. The Company has no contract or arrangement with any party in connection
with the solicitation of proxies.  Following the mailing of the Proxy materials,
solicitation  of Proxies may be made by officers and employees of the Company by
mail,  telephone,  facsimile,  electronic  communication or personal  interview.
Properly executed Proxies will be voted in accordance with instructions given by
stockholders at the places provided for such purpose in the accompanying  Proxy.
Unless contrary  instructions  are given by  stockholders,  persons named in the
proxy intend to vote the shares  represented by such Proxies for the election of
the five  nominees for director  named  herein,  and for the  selection of Grant
Thornton  LLP as  independent  auditors.  The  current  members  of the Board of
Directors  presently  hold voting  authority  for Common Stock  representing  an
aggregate  of 2,377,144  votes,  or  approximately  10.5% of the total number of
votes  eligible  to be cast at the Annual  Meeting.  The members of the Board of
Directors have indicated  their  intention to vote  affirmatively  on all of the
proposals.

                                VOTING SECURITIES

         Stockholders  of record as of the close of  business on the Record Date
will be entitled  to notice of, and to vote at, the Meeting or any  adjournments
thereof.  On the Record Date there were 22,696,238  outstanding shares of common
stock,  par value $.01 per share (the  "Common  Stock").  Each  holder of Common
Stock is entitled to one vote for each share held by such holder.  The presence,
in person or by proxy, of the holders of a majority of the outstanding shares of
Common  Stock is  necessary  to  constitute  a quorum  at the  Meeting.  Proxies
submitted which contain  abstentions or broker  non-votes will be deemed present
at the Meeting in determining the presence of a quorum.


                                       1


         SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

         The  following  table  sets  forth,  as  of  March  31,  2005,  certain
information  regarding the beneficial  ownership (as defined in Rule 13d-3 under
the  Securities  Exchange Act of 1934) of the Company's  Common Stock based upon
the most recent  information  available to the Company for (i) each person known
by the Company to own beneficially  more than five (5%) percent of the Company's
outstanding  Common  Stock,  (ii) each  director and nominee for director of the
Company,  (iii) each of the Company's Executive Officers, and (iv) all Executive
Officers and Directors of the Company as a group.  Unless  otherwise  indicated,
each  stockholder's  address  is  c/o  the  Company,   Three  University  Plaza,
Hackensack, New Jersey 07601.



                                                            Shares Owned Beneficially (1)
                                                     Amount and Nature
             Name and Address of                      of Beneficial
              Beneficial Owner                          Ownership                 Percent of Class
                                                                                  
Directors:

Todd Solomon (2)                                          3,158,413                     13.4%

Jack Abuhoff (3)                                          2,632,644                     10.4%

Charles Goldfarb (4)                                        114,487                      *

Haig S. Bagerdjian (5)                                       41,751                      *

John R. Marozsan (5)                                         31,251                      *

Louise C. Forlenza (6)                                       13,753                      *

Named Executive Officers:

Stephen Agress (7)                                          672,850                      2.9%

George Kondrach (8)                                         225,407                      *

All Executive Officers and Directors
as a Group (8 persons) (9)                                6,890,556                     26.6%


------------------------

* Less than 1%.

1.    Unless otherwise indicated, (i) each person has sole investment and voting
      power with respect to the shares  indicated and (ii) the shares  indicated
      are currently  outstanding shares. For purposes of this table, a person or
      group of persons is deemed to have "beneficial ownership" of any shares as
      of a given date which such person has the right to acquire  within 60 days
      after such date.  For purposes of computing the  percentage of outstanding
      shares  held by each  person or group of  persons  named  above on a given
      date,  any security  which such person or persons has the right to acquire
      within 60 days after such date is deemed to be outstanding for the purpose
      of computing the  percentage  ownership of such person or persons,  but is
      not deemed to be  outstanding  for the purpose of computing the percentage
      ownership of any other person.  Subject to the foregoing,  the percentages
      are calculated based on 22,693,138 shares outstanding.

2.    Includes  currently  exercisable  options to  purchase  930,253  shares of
      Common Stock.

3.    Includes  currently  exercisable  options to purchase  2,496,660 shares of
      Common Stock.

4.    Includes  currently  exercisable  options to  purchase  114,487  shares of
      Common Stock.

5.    Includes currently exercisable options to purchase 31,251 shares of Common
      Stock.

6.    Includes currently exercisable options to purchase 11,253 shares of Common
      Stock.

7.    Includes (i) currently  exercisable options held by Mr. Agress to purchase
      383,004 shares of Common Stock and (ii) currently exercisable options held
      by his  wife to  purchase  81,004  shares  of  Common  Stock.  Mr.  Agress
      disclaims  any  beneficial  ownership  in the  shares  issuable  upon  the
      exercise of options held by his wife.

8.    Includes  currently  exercisable  options to  purchase  190,632  shares of
      Common Stock.

9.    Includes  currently  exercisable  options to purchase  4,269,795 shares of
      Common Stock.


                                       2


                          ITEM I. ELECTION OF DIRECTORS

         It is the intention of the persons named in the enclosed form of Proxy,
unless  such form of Proxy  specifies  otherwise,  to  nominate  and to vote the
shares  represented  by such  Proxy for the  election  as  Directors  of Jack S.
Abuhoff,  Todd Solomon,  Haig S.  Bagerdjian,  Louise C.  Forlenza,  and John R.
Marozsan,  to hold office until the next Annual Meeting of Stockholders or until
their respective successors shall have been duly elected and qualified.  Each of
the nominees named below currently  serves as a Director of the Company and each
was elected at the Annual  Meeting of  Stockholders  held on June 15, 2004.  The
Company  has  no  reason  to  believe  that  any  of the  nominees  will  become
unavailable  to serve as  Director  for any reason  before  the Annual  Meeting.
However,  in the event that any of them shall  become  unavailable,  each of the
persons  designated as proxy reserves the right to substitute  another person of
his or her choice when voting at the Annual Meeting.



 Name                                Age                                    Position
 ----                                ---                                    --------
                                         
 Jack S. Abuhoff                     44        Chairman of the Board of Directors, Chief Executive
                                               Officer and President

 Todd Solomon                        43        Vice Chairman of the Board of Directors and Consultant

 Haig S. Bagerdjian                  48        Director

 Louise C. Forlenza                  55        Director

 John R. Marozsan                    63        Director


         Jack S. Abuhoff has been President and Chief  Executive  Officer of the
Company  since  September  15,  1997,  and a director of the  Company  since its
founding in 1988.  Mr.  Abuhoff has been the Chairman of the Company's  Board of
Directors since May 2001.  From 1995 to 1997 he was Chief  Operating  Officer of
Charles River Corporation,  an international systems integration and outsourcing
firm. From 1992 to 1994, Mr. Abuhoff was employed by Chadbourne & Parke, LLP, in
connection with its joint venture with Goldman Sachs to develop capital projects
in China. He practiced international corporate law at White & Case LLP from 1986
to 1992.  Mr.  Abuhoff  holds an A.B.  degree in English from  Columbia  College
(1983) and a J.D. degree from Harvard Law School (1986).

         Todd  Solomon  has been the Vice  Chairman  of the  Company's  Board of
Directors and a consultant to the Company since his resignation as President and
Chief  Executive  Officer on  September  15,  1997.  He served as the  Company's
President and one of the Company's Directors since the Company's founding by him
in 1988, and had been the Company's Chief  Executive  Officer since August 1995.
Mr. Solomon was President of Ruck Associates, an executive recruiting firm, from
1986 until 1987.  Mr.  Solomon holds an A.B.  degree in history and physics from
Columbia University (1986).


                                       3


         Haig S.  Bagerdjian has served as one of the Company's  directors since
June 2001. He has also been Chairman of the Board of Point.360 (Nasdaq: PTSX), a
provider of video and film asset  management  services to owners,  producers and
distributors of  entertainment  and advertising  content,  since September 2001.
From  1991 to 2002,  Mr.  Bagerdjian  served  in  various  executive  management
positions at Syncor International  Corporation (Nasdaq:  SCOR), an international
provider of high-technology  healthcare services primarily for radiopharmacy and
medical imaging segments of the healthcare  industry,  including  Executive Vice
President,  President  and Chief  Executive  Officer of Syncor  Overseas,  Ltd.,
Chairman and Chief  Executive  Officer of Syncor  Pharmaceuticals,  Inc.,  Chief
Legal Officer, and Senior Vice President,  Business Development.  Mr. Bagerdjian
also served as a director of Advanced Machine Vision Corporation (Nasdaq:  AMVC)
from 1997 until 2001. Mr.  Bagerdjian  received a B.A.  degree in  International
Relations  and Slavic  Languages and  Literature,  and  Certificates  in Russian
Studies,  Strategic  Defense  and  National  Security,  from the  University  of
Southern California (1983), and a J.D. degree from Harvard Law School (1986). He
is admitted to the State Bar of California.

         Louise C. Forlenza has served as one of the Company's  directors  since
October 2002.  From 1994 to the present,  Ms.  Forlenza has been providing audit
consultancy,  management advisory,  and tax planning services to a diverse group
of  corporate  clients.  From 1987  through  1992,  she was the Chief  Financial
Officer and Chief Operating Officer of  Intercontinental  Exchange Partners,  an
international foreign exchange company, and served as a director and as chair of
its  International  Audit  Committee.  Prior to  joining  Intercontinental,  Ms.
Forlenza was Chief  Financial  Officer of  Bierbaum-Martin,  a foreign  exchange
firm.  Ms.  Forlenza  participates   actively  in  various   not-for-profit  and
philanthropic  organizations  including as benefit chair for Greenwich  Hospital
and as Director  and  Treasurer  of The Acting  Company,  a New York  City-based
promoter  of arts and  literacy  founded  in 1972 by actor  John  Houseman.  Ms.
Forlenza also serves on the executive,  compensation  and finance  committees of
The Acting  Company.  She is a  certified  public  accountant  and served on the
faculty of the  accounting  department  of Iona College  from 1981 to 1982.  Ms.
Forlenza received a B.B.A. degree in Accounting from Iona College (1971).

         John R.  Marozsan has served as one of the  Company's  directors  since
June 2001. In 1999, Mr. Marozsan retired as President,  Chief Executive  Officer
and as a member  of the  Executive  Committee  of CCH  Incorporated,  a  leading
provider of tax and  business law  information.  He was a member of the board of
directors of Wolters  Kluwer U.S.,  of which CCH is a  wholly-owned  subsidiary,
until June 1999. From 1986 until joining CCH in 1996, Mr. Marozsan was President
and Chief  Executive  Officer of Aspen  Publishers,  Inc., also a Wolters Kluwer
U.S. company. Before that, he spent 10 years in a number of management positions
at Aspen Publishers, Inc., including Editor-in-Chief and Publisher. Mr. Marozsan
received a B.S. degree in physics from Trenton State College (1967), and an M.A.
degree from Harvard University (1970).

         There are no family relationships between or among any Directors of the
Company.  Directors  are  elected  to serve  until the next  annual  meeting  of
stockholders and until their successors are elected and qualified.


                                       4


Independent Directors

         The Board of Directors is  currently  comprised of six (6) members,  of
which four (4) are classified as "independent" as defined in the Nasdaq National
Market's Marketplace Rule 4200. The independent directors comprise a majority of
the Board.  The four  independent  directors are Haig S.  Bagerdjian,  Louise C.
Forlenza,  Charles F.  Goldfarb and John R.  Marozsan.  

Meetings of the Board of Directors

         The Board of Directors meets throughout the year on a set schedule. The
Board of Directors  also holds  special  meetings and acts by unanimous  written
consent  from time to time as  appropriate.  The Board of  Directors  held seven
meetings  during the year ended  December 31, 2004.  Each  director  attended at
least (i) 75% of all of the meetings of the Board of  Directors  held during the
period and (ii) 75% of the meetings of each committee on which he or she served.
The Company does not have a policy  requiring  incumbent  directors and director
nominees to attend the Company's annual meeting of  stockholders.  One incumbent
director attended last year's annual meeting.

         The Board of Directors meets in executive sessions without  management,
as needed, during or immediately following its regularly scheduled meetings. The
Board of Directors also  schedules  executive  sessions  during the year for the
independent directors only.

Committees of the Board of Directors

         The  Company  has a  separately  designated  standing  Audit  Committee
established in accordance with Section  3(a)(58)(A) of the Exchange Act. Serving
on the Committee are Messrs. Marozsan and Bagerdjian and Ms. Forlenza. The Board
of Directors has  determined  that it has an audit  committee  financial  expert
serving on the audit  committee,  Ms.  Forlenza.  Ms. Forlenza is an independent
director as defined in Item  7(d)(3)(iv)  of Schedule  14A. The functions of the
Audit Committee are, among other things, to make recommendations  concerning the
selection  each year of  independent  auditors  of the  Company,  to review  the
effectiveness of the Company's internal  accounting  methods and procedures,  to
consider  whether the Company's  principal  accountant's  provision of non-audit
services is compatible with maintaining the principal accountant's  independence
and to determine through  discussions with the independent  auditors whether any
instructions  or limitations  have been placed upon them in connection  with the
scope of their audit or its implementation.  To carry out its  responsibilities,
the Audit  Committee met eight times during fiscal 2004.  The Board of Directors
has  determined  that the members of the Audit  Committee are  "independent"  as
defined in the Nasdaq National Market's Marketplace Rule 4200.

         The Company has a standing Compensation  Committee comprised of Messrs.
Bagerdjian  and Marozsan  and Ms.  Forlenza.  The  function of the  Compensation
Committee  is to  discharge  the  responsibilities  of the  Board  of  Directors
regarding  executive   compensation,   including  determining  the  compensation
packages of the Company's  Executive  Officers,  including  its Chief  Executive
Officer. To carry out its responsibilities, the Compensation Committee met three
times during fiscal 2004. The Board of Directors has determined that the members
of the  Compensation  Committee  are  "independent"  as  defined  in the  Nasdaq
National Market's Marketplace Rule 4200.


                                       5


         The Company does not have a standing Nominating  Committee.  Due to the
size of the Company and the resulting efficiency of a Board of Directors that is
also limited in size, as well as the minimal  turnover in the Company's Board of
Directors,  the Board of Directors  has  determined  that it is not necessary or
appropriate at this time to establish a separate Nominating Committee. Potential
candidates  for  director are  reviewed by the entire  Board of  Directors,  and
director nominees are selected by Board of Director  resolutions  subject to the
approval  of a  majority  of the  independent  directors.  All  of the  nominees
recommended  for election to the Board of  Directors at the Annual  Meetings are
directors  standing for  re-election.  Although  the Board of Directors  has not
established any minimum qualifications for director candidates, when considering
potential director candidates,  the Board of Directors considers the candidate's
character,  judgment,  diversity,  skills,  including  financial  literacy,  and
experience  in the  context  of the  needs  of the  Company  and  the  Board  of
Directors. In 2004 the Company did not pay any fees to any third party to assist
in identifying or evaluating potential nominees.

         The Company's  By-laws include a procedure whereby its stockholders can
nominate director  candidates,  as more fully described below under "Stockholder
Proposals  for the 2006 Annual  Meeting."  The Board of Directors  will consider
director  candidates  recommended  by the  Company's  stockholders  in a similar
manner  as those  recommended  by  members  of  management  or other  directors,
provided the  stockholder  submitting  such  nomination  has  complied  with the
procedures  set forth in its By-laws.  To date, the Company has not received any
recommended   nominees  from  any   non-management   stockholder   or  group  of
stockholders that beneficially owns five percent or more of its voting stock.

                          REPORT OF THE AUDIT COMMITTEE

         The  following  report  of the  Audit  Committee  does  not  constitute
soliciting  material and should not be deemed filed or incorporated by reference
into any other Company filing under the Securities Act of 1933 or the Securities
Exchange Act of 1934, except to the extent the Company specifically incorporates
this Report by reference therein.

         The responsibilities of the Audit Committee, which are set forth in the
Audit Committee Charter,  include providing oversight to the Company's financial
reporting  process  through  periodic  meetings with the  Company's  independent
accountants and management to review accounting, auditing, internal controls and
financial  reporting  matters.  The Audit Committee is also  responsible for the
appointment,  compensation and oversight of the Company's  independent auditors.
The management of the Company is responsible  for the  preparation and integrity
of the financial reporting information and related systems of internal controls.
The Audit  Committee,  in carrying out its role,  relies on the Company's senior
management,   including  senior  financial   management,   and  its  independent
accountants.

         The Audit  Committee has  implemented  procedures to ensure that during
the course of each fiscal year it devotes the attention that it deems  necessary
or appropriate to each of the matters assigned to it under the Audit Committee's
charter. To carry out its responsibilities,  the Audit Committee met eight times
during fiscal 2004.


                                       6


         The primary  purpose of the Audit  Committee  is to assist the Board of
Directors in fulfilling its oversight  responsibilities  relating to the quality
and  integrity  of the  Company's  financial  reports  and  financial  reporting
processes  and  systems of  internal  controls.  Management  of the  Company has
primary  responsibility for the Company's  financial  statements and the overall
reporting  process,  including  maintenance of the Company's  system of internal
controls.  The Company  retains  independent  auditors who are  responsible  for
conducting  an  independent  audit of the  Company's  financial  statements,  in
accordance  with generally  accepted  auditing  standards,  and issuing a report
thereon.

         In  performing  its  duties,  the  Audit  Committee  has  reviewed  and
discussed the audited  financial  statements  with  management and the Company's
independent auditors.  The Audit Committee has also discussed with the Company's
independent  auditors,  the matters  required to be  discussed  by  Statement of
Auditing  Standards ("SAS") No. 61,  "Communications  with Audit Committee." SAS
No. 61 requires the  independent  auditors to provide the Audit  Committee  with
additional  information  regarding  the scope and  results of their audit of the
Company's   financial   statements,   including   with   respect  to  (i)  their
responsibility  under auditing standards generally accepted in the United States
of America, (ii) significant accounting policies, (iii) management judgments and
estimates,  (iv) any significant audit  adjustments,  (v) any disagreements with
management,  and (vi) any  difficulties  encountered in performing the audit. In
addition,  the Audit Committee received written  disclosures and the letter from
the independent auditors required by Independence  Standards Board Statement No.
1, "Independence  Discussions with Audit Committees".  The independent  auditors
have discussed its independence with the Audit Committee,  and have confirmed to
the Audit Committee that, in its professional judgment, it is independent of the
Company within the meaning of the federal securities laws.

         On the  basis of the  foregoing  reviews  and  discussions,  the  Audit
Committee  recommended  to the Board of  Directors  that the  audited  financial
statements  be  included  in the  Company's  Annual  Report on Form 10-K for the
fiscal year ended December 31, 2004, for filing with the Securities and Exchange
Commission.  The Audit  Committee has also  recommended,  subject to shareholder
approval, the selection of the Company's independent auditors.

                                 Audit Committee

                           John R. Marozsan - Chairman
                               Haig S. Bagerdjian
                               Louise C. Forlenza

Fiscal 2004 and 2003 Accounting Firm Fee Summary

         Set forth below is certain  information  concerning  fees billed to the
Company by Grant  Thornton LLP and its  international  affiliates  in respect of
services provided for 2004 and 2003. The Audit Committee has determined that the
provision of all services is compatible  with  maintaining  the  independence of
Grant Thornton LLP.


                                       7


         Audit Fees. Grant Thornton LLP and its international  affiliates billed
the Company aggregate fees of approximately  $260,000 for professional  services
rendered for (1) the audit of the annual financial  statements for 2004, (2) the
reviews of the financial statements included in reports on Form 10-Q for periods
within 2004 and (3) related regulatory filings;  and approximately  $150,000 for
professional  services  rendered  for  (1) the  audit  of the  annual  financial
statements for 2003 and (2) the reviews of the financial  statements included in
reports on Form 10-Q for periods within 2003.

         Audit Related Fees. Grant Thornton LLP and its international affiliates
billed the Company aggregate fees of approximately  $11,000 and $5,000 for audit
related services rendered in 2004 and 2003, respectively.

         Tax Fees. Grant Thornton LLP and its  international  affiliates  billed
the Company  aggregate fees of approximately  $16,000 and $5,000 for tax related
services rendered in 2004 and 2003 respectively.

         Other Fees. Grant Thornton LLP and its international affiliates did not
provide any other services to the Company in 2004 or 2003.

         Audit Committee Pre-Approval Policy. All audit, audit-related services,
tax  services  and  other  services  provided  by  Grant  Thornton  LLP  must be
pre-approved  by the Audit  Committee.  The Audit  Committee may delegate to its
Chair the authority to pre-approve  otherwise  permissible  non-audit  services,
provided that any decision made pursuant to such delegation must be presented to
the full  Audit  Committee  for  informational  purposes  at its next  scheduled
meeting.

Compliance with Section 16(a) of the Exchange Act

         The  Company  believes  that  during  the period  from  January 1, 2004
through  December 31, 2004 all officers,  directors and greater than ten-percent
beneficial owners complied with Section 16(a) filing requirements.

Stockholders Communications with the Board of Directors

         Generally,  stockholders  who have questions or concerns  regarding the
Company  should  contact our  Investor  Relations  department  at  201-488-1200.
However,  stockholders  may communicate with the Board of Directors by sending a
letter to: Board of Directors of Innodata Isogen, Inc., c/o Corporate Secretary,
3 University  Plaza,  Hackensack,  New Jersey  07601.  Any  communications  must
contain  a  clear  notation   indicating   that  it  is  a   "Stockholder--Board
Communication" or a "Stockholder--Director  Communication" and must identify the
author as a stockholder.  The office of the Corporate Secretary will receive the
correspondence  and forward  appropriate  correspondence  to the Chairman of the
Board or to any individual  director or directors to whom the  communication  is
directed.  The  Company  reserves  the  right  not to  forward  to the  Board of
Directors any  communication  that is hostile,  threatening,  illegal,  does not
reasonably relate to the Company or its business, or is similarly inappropriate.
The office of the Corporate  Secretary has authority to discard or disregard any
inappropriate  communication  or to take any  other  action  that it deems to be
appropriate with respect to any inappropriate communications.


                                       8


                               EXECUTIVE OFFICERS

         Set forth below is information  concerning  the Executive  Officers who
are not Directors.

 Name                                 Age             Position
 ----                                 ---             --------

 George Kondrach                      52              Executive Vice President
 Stephen Agress                       43              Vice President - Finance

         Mr. George  Kondrach has been the Company's  Executive  Vice  President
since May 2003. From December 2001 to May 2003, he served as President of Isogen
International,  LLC, a wholly-owned subsidiary of the Company. Mr. Kondrach, who
in 1991  co-founded  Isogen  International,  served as its Chairman  until April
1999,  when it was  acquired by  DataChannel,  Inc.  From 1999 until the Company
acquired  the Isogen  International  division of  DataChannel,  Inc. in December
2001,  Mr.  Kondrach  served  in  various  executive  management  capacities  at
DataChannel,   Inc.,  most  recently  as  Senior  Vice  President  of  Solutions
Architecture.  Mr.  Kondrach  holds  a B.S.  degree  in  biology  from  Southern
Methodist University (1975).

         Mr.  Stephen  Agress has been the  Company's  Vice  President - Finance
since March 1998.  Before that, he served as Corporate  Controller since joining
the Company in August 1995. Mr. Agress is a certified public  accountant and was
a senior  audit  manager at Deloitte & Touche LLP for more than five years prior
to his  resignation in 1995. Mr. Agress holds a B.S.  degree in accounting  from
Yeshiva University (1982).

         The  Company's  Executive  Officers  are  elected  by and  serve at the
discretion of our Board of Directors.  There are no family relationships between
or among any of the Company's Executive Officers.  Stephen Agress, the Company's
Vice  President-Finance,  is the husband of the  Company's  Vice  President  and
General Counsel, who is not an Executive Officer.


                                       9


                       EXECUTIVE AND DIRECTOR COMPENSATION

         The following table sets forth information with respect to compensation
paid by the Company for  services to the Company  during the three  fiscal years
ended  December  31,  2004  to the  Chief  Executive  Officer  and to all  other
Executive  Officers whose total annual salary and bonuses  exceeded  $100,000 in
2004.

                           SUMMARY COMPENSATION TABLE



                                                                 Annual Compensation
                                                                 -------------------
                                           Calendar                                                Stock Options
             Name and Position               Year              Salary             Bonus               Awarded
                                                                                      
Jack Abuhoff                                2004            $355,650           $284,520             100,000
Chairman of the Board of                    2003             315,600             63,120             337,500 (a)
Directors, Chief Executive                  2002             315,600                 --           1,139,160 (b)
Officer and President

George Kondrach                             2004            $250,000            $86,250                  --
Executive Vice President                    2003             216,667             68,333             200,000
                                            2002             200,000             10,660             150,000

Stephen Agress                              2004            $184,900            $88,421                  --
Vice President - Finance                    2003             169,000             25,350             168,000 (a);
                                                                                                     40,000
                                            2002             169,000                 --                  --


(a)   Represents  options  granted in prior years for which the expiration  date
      was extended for 10 years.

(b)   Represents  options  granted  in 1997 for  which the  expiration  date was
      extended from 2002 to 2007.

The above  compensation  does not include certain other personal  benefits,  the
total value of which does not exceed as to any Executive Officer,  the lesser of
$50,000 or 10% of such person's cash  compensation.  The Company has not granted
any stock appreciation rights nor does it have any "long-term  incentive plans,"
other than its stock option plans.


                                       10


                        OPTION GRANTS IN LAST FISCAL YEAR
                                Individual Grants



                                                                                                    Potential Realized
                          Number of                                                                  Value at Assumed
                         Securities            Percent of                                            Annual Rates of
                         Underlying          Total Options          Exercise                        Stock Appreciation
                           Options        Granted to Employees        Price     Expiration           For Option Term
Name                       Granted           In Fiscal Year        Per Share        Date            5%             10%
                                                                                             
Jack Abuhoff               100,000                 47%                $3.75         8/14        $235,835       $597,653


                 AGGREGATE OPTION EXERCISES IN LAST FISCAL YEAR;
                          FISCAL YEAR END OPTION VALUES



                           Shares                         Number of Unexercised           Value of Unexercised In-the-
                          Acquired        Value        Options at Fiscal Year End       Money Options at Fiscal Year End
Name                    on Exercise      Realized       Exercisable/Unexercisable           Exercisable/Unexercisable
                                                                                  
Jack Abuhoff                 --             --              2,496,660/100,000                 $24,567,134/$984,000

George Kondrach              --             --               154,180/195,820                  $1,517,131/$1,926,869

Stephen Agress               --             --               376,743/31,257                    $3,707,151/$307,569


Employment Agreements

         On January 1, 2004,  the Company  entered  into a four year  employment
agreement  with Mr. George  Kondrach to serve as Executive Vice President of the
Company.  Pursuant to the agreement,  Mr. Kondrach will be compensated at a rate
of  $250,000  per  annum for the  first  year,  subject  to  annual  review  for
discretionary  annual increases  thereafter,  and will be eligible to receive an
annual cash bonus, the amount of which will be based upon meeting certain goals.

Directors Compensation

         Messrs. Bagerdjian and Marozsan and Ms. Forlenza are compensated at the
rate of  $1,250  per  month,  plus  out-of-pocket  expenses  for  each  Board of
Directors meeting they attend.

         Dr.  Charles F. Goldfarb is  compensated at a rate of $1,250 per month,
plus out-of-pocket  expenses for each Board of Directors meeting he attends. Dr.
Goldfarb also receives $750 per month for additional  services he renders to the
Company.

         The  Company  has an  arrangement  with Mr.  Todd  Solomon,  its former
President and Chief Executive Officer, that provides for a salary of $75,000 per
annum.


                                       11


         The  Directors  do  not  receive  any  compensation  for  serving  on a
Committee of the Board of Directors.

Compensation Committee Interlocks and Insider Participation

         In 2004 the Compensation Committee was comprised of Messrs.  Bagerdjian
and Marozsan and Ms. Forlenza, none of whom are or were officers or employees of
the Company.

                 REPORT OF THE EXECUTIVE COMPENSATION COMMITTEE

         The  Executive   Compensation  Committee  (the  "Committee")  sets  and
administers the policies  governing  annual  compensation of the Chief Executive
Officer  and the other  Executive  Officers.  The  Committee  consists  of three
directors who meet the independence requirements of the Nasdaq Stock Market. The
Committee  acts under a charter that was approved by the full Board of Directors
on December 16, 2002. The Committee met three times in 2004.

Compensation Principles

         The Committee  seeks to establish an appropriate  relationship  between
executive  compensation  and the creation of shareholder  value. To achieve this
goal, the Company's executive  compensation  consists of a combination of annual
salary, bonuses based upon targeted financial goals, and stock-based incentives.

         The Committee determines  compensation  annually by considering (a) the
level of compensation  necessary to attract and retain executive talent in light
of compensation paid by peer companies and the overall competitive  environment,
(b) Company  performance,  both separately and in relation to similar companies,
(c) individual performance,  (d) historical compensation levels and stock awards
at the Company,  (e) recommendations by an independent  compensation  consulting
firm, and (f) any other factors the Committee may deem  relevant.  The Committee
also  considers  the   recommendations   of  the  Chief  Executive   Officer  on
compensation for other Executive Officers.

Base Salary

         The Company provides competitive base salaries that allow it to attract
and retain a high  performing  leadership  team.  Base  salaries  for  Executive
Officers are  determined  based on an  assessment of the factors set forth above
under Compensation Principles.

Annual Bonuses

         In  2004,  the  Company's  Executive  Officers,   including  its  Chief
Executive  Officer,  were eligible to receive an annual bonus in accordance with
executive management incentive compensation plans adopted for calendar year 2004
(the  "Plans").  Each Plan  participant's  bonus was based on either or both of:
earnings before  interest,  taxes and executive  incentives  (EBITe),  and sales
performance as measured by bookings and revenues  (bookings and  revenues).  The
bonus paid to the each  participant  was based on the variance in the  Company's
results above or below the goals set for each performance factor.


                                       12


See the  "Summary  Compensation  Table"  for  amounts  paid to  Named  Executive
Officers in 2004, including salary and bonus.

Stock-based Incentives

         The  Company  uses  stock  option  grants as the  primary  vehicle  for
employee stock-based incentives.  The Committee believes stock options align the
Executives  Officers'  interests  with those of  stockholders  in building share
value,  offer  Executive  Officers an incentive for the  achievement of superior
performance over time, and foster the retention of key management personnel. The
Committee  typically  grants stock options on an annual basis,  and occasionally
makes supplemental grants. Stock options have an exercise price equal to current
market  price  at time of  grant,  and vest  over  time to  encourage  Executive
Officers to remain  employed  with the Company.  The number of stock options the
Committee  awards  each  Executive  Officer  is  based  on his  or her  relative
position, responsibilities and performance over the previous fiscal year and his
or her  anticipated  future  performance,  potential and  responsibilities.  The
Committee also reviews prior stock option grants to each  Executive  Officer and
others,  including  the number of stock  options that  continue to be subject to
vesting under their  respective  grants.  The size of stock option grants is not
directly related to the Company's  performance.  The Committee also uses data on
stock options  granted by companies that are comparable by industry and revenue,
and  takes  into  consideration   recommendations  asserted  by  an  independent
compensation consulting firm.

No stock-based incentives were paid to Named Executive Officers,  other than the
Chief Executive Officer, in 2004.

Chief Executive Officer Compensation

         For 2004, the Committee  determined the salary,  bonus and  stock-based
incentives of the Chief Executive Officer  substantially in conformance with the
policies  described above for all Executive  Officers of the Company.  On August
19, 2004 the  Committee  approved an increase in the Chief  Executive  Officer's
base salary from $315,600 to $369,000, retroactive to April 1, 2004, and awarded
to the Chief Executive  Officer stock options to purchase  100,000 shares of the
Company's  common stock.  In addition,  based on the Company's  earnings  before
interest,  taxes and executive  incentives (EBITe),  the Chief Executive Officer
received  a  bonus  of  $284,520  under  his  executive   management   incentive
compensation plan.

                        Executive Compensation Committee

                          Haig S. Bagerdjian, Chairman
                                 Louise Forlenza
                                John R. Marozsan


                                       13


                          STOCK PRICE PERFORMANCE GRAPH

         The following  performance  graph compares the cumulative  total return
(assuming  reinvestment  of  dividends)  of an  investment  of $100 in  Innodata
Isogen, Inc. on January 1, 2000 through its fiscal year ended December 31, 2004,
to the Nasdaq Market Index and the Industry Index for SIC Code 7374, Information
Retrieval Services.

                     COMPARE 5-YEAR CUMULATIVE TOTAL RETURN
                          AMONG INNODATA ISOGEN, INC.,
                     NASDAQ MARKET INDEX AND SIC CODE INDEX

  [THE FOLLOWING TABLE WAS REPRESENTED AS A LINE GRAPH IN THE PRINTED MATERIAL]



                              1999       2000       2001      2002       2003       2004
                                                                 
INNODATA ISOGEN, INC         100.00     277.16     149.67     48.38     201.57     495.87
SIC CODE INDEX               100.00      89.39      91.83     70.37      83.76      92.00
NASDAQ MARKET INDEX          100.00      62.85      50.10     34.95      52.55      56.97


                     ASSUMES $100 INVESTED ON JAN. 1, 2000
                          ASSUMES DIVIDEND REINVESTED
                        FISCAL YEAR ENDING DEC. 31, 2004

                 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

         In May 2001,  the Company  entered  into an  agreement  with Mr.  Barry
Hertz, then the Chairman of the Board of Directors,  pursuant to which Mr. Hertz
is  continuing  to serve as a  part-time  employee of the Company at a salary of
$2,000 per month for five years. In addition, the Company paid Mr. Hertz at that
time $400,000 for entering into a six-year  non-competition  agreement  with the
Company.


                                       14


          ITEM II. RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITORS

         Subject to approval by the  stockholders,  the Board of  Directors  has
appointed Grant Thornton LLP as the independent  auditors to audit the financial
statements  of the Company for the fiscal year ending  December 31, 2005.  Grant
Thornton LLP has served as the  Company's  auditors for each of the fiscal years
ended since  December  31,  1997.  A  representative  of Grant  Thornton  LLP is
expected to be present at the Annual Meeting and to have the opportunity to make
a statement if they desire to do so. A  representative  of Grant Thornton LLP is
also  expected  to be  available  to respond  to  appropriate  questions  at the
meeting.

         In the event that the  stockholders  fail to ratify  this  appointment,
other certified public accountants will be considered upon recommendation of the
Audit Committee.  Even if this appointment is ratified,  our Board of Directors,
in its discretion,  may direct the  appointment of a new independent  accounting
firm at any time during the year, if the Board believes that such a change would
be in the best interest of the Company and its stockholders.

    THE BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE FOR RATIFICATION OF THE
            APPOINTMENT OF GRANT THORNTON LLP AS INDEPENDENT AUDITORS

                                  VOTE REQUIRED

         Election of  Directors.  Directors  will be elected at the meeting by a
plurality  of the votes cast (i.e.,  the five  nominees  receiving  the greatest
number of votes will be elected as Directors).

         Ratification   of  the   Appointment  of  Independent   Auditors.   The
appointment  of  Grant  Thornton  LLP  as  independent   auditors  requires  the
affirmative vote of a majority of the shares present in person or represented by
proxy at the meeting and entitled to vote on the matter.  Abstentions  will have
the same effect as a vote against such  ratification,  whereas broker  non-votes
and shares not  represented  at the meeting  will not be counted for purposes of
determining whether such ratification has been approved.


                                       15


                             EXPENSE OF SOLICITATION

         The cost of soliciting  proxies,  which also includes the  preparation,
printing  and  mailing  of the Proxy  Statement,  will be borne by the  Company.
Solicitation will be made by the Company primarily through the mail, but regular
employees of the Company may solicit proxies personally, by telephone, facsimile
or electronic  communication.  The Company will request  brokers and nominees to
obtain voting instructions of beneficial owners of the stock registered in their
names and will reimburse them for any expenses incurred in connection therewith.

                STOCKHOLDER PROPOSALS FOR THE 2006 ANNUAL MEETING

Notice Required to Include Proposals in Our Proxy Statement

         We will review for inclusion in next year's proxy statement shareholder
proposals   received  by  December  31,  2005.   All  proposals  must  meet  the
requirements  set forth in the rules and  regulations  of the SEC in order to be
eligible  for  inclusion  in the proxy  statement.  Proposals  should be sent to
Innodata Isogen,  Inc., Three University  Plaza,  Hackensack,  New Jersey 07601,
Attention: Corporate Secretary.

Notice Required to Bring Business Before an Annual Meeting

         Our by-laws  establish an advance notice  procedure for stockholders to
make  nominations  of  candidates  for  election  of  director or to bring other
business before an annual meeting.  Under these  procedures,  a stockholder that
proposes to nominate a candidate for director or propose  other  business at the
2006  annual  meeting  of  stockholders,  must  give us  written  notice of such
nomination  or proposal not less than 60 days and not more than 90 days prior to
the  scheduled  date of the meeting  (or, if less than 70 days'  notice or prior
public  disclosure of the date of the meeting is given,  then not later than the
15th day  following  the  earlier of (i) the date such notice was mailed or (ii)
the day such public  disclosure  was made).  Such notice  must  provide  certain
information  as specified  in our by-laws and must be received at our  principal
executive offices by the deadline specified above.

                                  OTHER MATTERS

         The  Company  knows of no items of  business  that are  expected  to be
presented  for  consideration  at the Annual  Meeting  which are not  enumerated
herein.  However,  if other  matters  properly  come before the  Meeting,  it is
intended  that the person named in the  accompanying  Proxy will vote thereon in
accordance with his best judgment.


                                       16


         PLEASE  DATE,   SIGN  AND  RETURN  THE  PROXY  CARD  AT  YOUR  EARLIEST
CONVENIENCE IN THE ENCLOSED RETURN ENVELOPE. NO POSTAGE IS REQUIRED IF MAILED IN
THE UNITED STATES.  A PROMPT RETURN OF YOUR PROXY CARD WILL BE APPRECIATED AS IT
WILL SAVE THE EXPENSE OF FURTHER MAILINGS.

Hackensack, New Jersey             By Order of the Board of Directors
April 19, 2005

                                   Amy R. Agress
                                   Vice President, General Counsel and Secretary


                                       17


                        ANNUAL MEETING OF STOCKHOLDERS OF

                              INNODATA ISOGEN, INC.

                                  June 7, 2005

                           Please date, sign and mail
                             your proxy card in the
                            envelope provided as soon
                                  as possible.

     Please detach along perforated line and mail in the envelope provided.

--------------------------------------------------------------------------------
        PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.
           PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE       |X|
--------------------------------------------------------------------------------

1. Election of Directors:

                                    NOMINEES:
|_| FOR ALL NOMINEES                o Jack Abuhoff
                                    o Todd Solomon
                                    o Haig S. Bagerdjian
|_| WITHHOLD AUTHORITY              o Louise C. Forlenza
    FOR ALL NOMINEES                o John R. Marozsan

|_| FOR ALL EXCEPT
    (See instructions below)

INSTRUCTION: To withhold authority to vote for any individual  nominee(s),  mark
             "FOR ALL EXCEPT"  and  fill in the circle next to each  nominee you
             wish to withhold, as shown here:  *

                                                        FOR   AGAINST    ABSTAIN
2. Ratification of the selection of Grant Thornton      |_|     |_|        |_|
   LLP as independent auditors.

THE SHARES REPRESENTED BY THIS PROXY, DULY EXECUTED, WILL BE VOTED IN ACCORDANCE
WITH  THE  SPECIFICATIONS   MADE.  IF  NO  SPECIFICATION  IS  MADE,  THE  SHARES
REPRESENTED BY THIS PROXY WILL BE VOTED IN FAVOR OF EACH OF THE ABOVE  NOMINEES,
FOR SELECTION OF GRANT THORNTON LLP AS INDEPENDENT AUDITORS,  AND FOR SUCH OTHER
MATTERS AS MAY  PROPERLY  COME  BEFORE  THE  MEETING  AS THE  PROXYHOLDERS  DEEM
ADVISABLE.

TO ASSURE YOUR REPRESENTATION AT THE ANNUAL MEETING,  PLEASE MARK, SIGN AND DATE
THIS PROXY AND RETURN IT PROMPTLY IN THE ENCLOSED ENVELOPE.



--------------------------------------------------------------------------------

To change the address on your account,  please check the box       |_|
at right and indicate  your new address in the address space
above. Please note that changes to the registered name(s) on
the account may not be submitted via this method.

                         ----------------------------------        ------------
Signature of Stockholder                                     Date:
                         ----------------------------------        ------------

                         ----------------------------------        ------------
Signature of Stockholder                                     Date:
                         ----------------------------------        ------------

Note:    Please sign  exactly as your name or names  appear on this Proxy.  When
         shares are held  jointly,  each holder  should  sign.  When  signing as
         executor,  administrator,  attorney,  trustee or guardian,  please give
         full title as such.  If the signer is a  corporation,  please sign full
         corporate name by duly authorized  officer,  giving full title as such.
         If  signer  is a  partnership,  please  sign  in  partnership  name  by
         authorized person.


                              INNODATA ISOGEN, INC.
                         ANNUAL MEETING OF STOCKHOLDERS

           THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

         The undersigned  Stockholder of Common Stock of Innodata  Isogen,  Inc.
(the "Company") hereby revokes all previous proxies, acknowledges receipt of the
Notice of the  Meeting of  Stockholders  to be held on June 7, 2005,  and hereby
appoints Jack S. Abuhoff and Amy R. Agress,  and each of them, as proxies of the
undersigned,  with full power of substitution,  to vote and otherwise  represent
all of the shares of the  undersigned  in the Company at said meeting and at any
adjournments thereof with the same effect as if the undersigned were present and
voting the shares.  The shares  represented  by this proxy shall be voted on the
following  matters and, in their  discretion,  upon any other business which may
properly come before said meeting.

                (Continued and to be signed on the reverse side)

                                                                           14475